The following video is part of our "Motley Fool Conversations" series, in which David Williamson, health-care editor and analyst, and Brendan Byrnes, industrials editor and analyst, discuss topics across the investing world.
In today's edition, David and Brendan discuss the recent trend of biotech companies teaming up with generic manufacturers to create generic biologic drugs. There is currently no easy pathway to approval for biosimilars, but with one potentially coming thanks to the Affordable Care Act, we could see an increase of the cheaper drugs. How will this impact the industry going forward? Watch and find out.
Looking for our prediction for 2012? Check out The Motley Fool's brand-new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.
